

Please add the following new claims:

Sub
C46

--27. An isolated protein comprising amino acids 1 to 245 of SEQ ID NO:26.

28. The isolated protein of claim 27, which comprises amino acids -38 to 245 of SEQ ID NO:26.

29. The isolated protein of claim 27, which is produced by a recombinant host cell.

30. The isolated protein of claim 27, which comprises a heterologous polypeptide.

31. The isolated protein of claim 30, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

32. A composition comprising the isolated protein of claim 27 and a pharmaceutically acceptable carrier.

33. An isolated protein comprising the mature amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97059.

34. The isolated protein of claim 33, which comprises the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97059.

35. The isolated protein of claim 33, which is produced by a recombinant host cell.

00340300-06904E60

B4

Sub
E1

Sub
C46

36. The isolated protein of claim 33, which comprises a heterologous polypeptide.
37. The isolated protein of claim 36, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
38. A composition comprising the isolated protein of claim 33 and a pharmaceutically acceptable carrier.
39. An isolated protein comprising 30 contiguous amino acids of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97059.
40. The isolated protein of claim 39, which comprises 50 contiguous amino acids of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97059.
41. The isolated protein of claim 39, which is produced by a recombinant host cell.
42. The isolated protein of claim 39, which comprises a heterologous polypeptide.
43. The isolated protein of claim 42, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
44. A composition comprising the isolated protein of claim 39 and a pharmaceutically acceptable carrier.

B4
Cont
566290 06904E60
Sub
E3

45. An isolated protein comprising the mature amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97058.

46. The isolated protein of claim 45, which comprises the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97058.

47. The isolated protein of claim 45, which is produced by a recombinant host cell.

48. The isolated protein of claim 45, which comprises a heterologous polypeptide.

49. The isolated protein of claim 48, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

50. A composition comprising the isolated protein of claim 45 and a pharmaceutically acceptable carrier.

51. An isolated protein comprising 30 contiguous amino acids of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97058.

52. The isolated protein of claim 51, which comprises 50 contiguous amino acids of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97058.

53. The isolated protein of claim 51, which is produced by a recombinant host cell.

Sub
C48

09340690-06904E60

B4
Cont
Sub
E4

54. The isolated protein of claim 51, which comprises a heterologous polypeptide.
55. The isolated protein of claim 54, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
56. A composition comprising the isolated protein of claim 51 and a pharmaceutically acceptable carrier.
57. An isolated protein comprising the mature amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97057.
58. The isolated protein of claim 57, which comprises the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97057.
59. The isolated protein of claim 57, which is produced by a recombinant host cell.
60. The isolated protein of claim 57, which comprises a heterologous polypeptide.
61. The isolated protein of claim 60, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
62. A composition comprising the isolated protein of claim 57 and a pharmaceutically acceptable carrier.

09340690-06904E60
By
Cmt.

Sub
E3

63. An isolated protein comprising 30 contiguous amino acids of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97057.
64. The isolated protein of claim 63, which comprises 50 contiguous amino acids of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97057.
65. The isolated protein of claim 63, which is produced by a recombinant host cell.
66. The isolated protein of claim 63, which comprises a heterologous polypeptide.
67. The isolated protein of claim 66, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
68. A composition comprising the isolated protein of claim 63 and a pharmaceutically acceptable carrier.
69. An isolated protein comprising a fragment of the amino acid sequence of SEQ ID NO:26; wherein said protein binds to an antibody having specificity for a polypeptide consisting of the complete amino acid sequence of SEQ ID NO:26.
70. The isolated protein of claim 69, which is produced by a recombinant host cell.
71. The isolated protein of claim 69, which comprises a heterologous polypeptide.

06904260-066290

B4
cont

72. The isolated protein of claim 71, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

73. A composition comprising the isolated protein of claim 69 and a pharmaceutically acceptable carrier.

74. An isolated protein comprising a fragment of an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:5, wherein said protein binds to an antibody having specificity for a polypeptide consisting of the complete amino acid sequence of SEQ ID NO:5; and

(b) the amino acid sequence of SEQ ID NO:8, wherein said protein binds to an antibody having specificity for a polypeptide consisting of the complete amino acid sequence of SEQ ID NO:8.

75. The isolated protein of claim 74, which comprises a fragment of SEQ ID NO:5.

76. The isolated protein of claim 74, which comprises a fragment of SEQ ID NO:8.

77. The isolated protein of claim 74, which is produced by a recombinant host cell.

78. The isolated protein of claim 74, which comprises a heterologous polypeptide.

06904E60

By
Cont

79. The isolated protein of claim 78, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

80. A composition comprising the isolated protein of claim 74 and a pharmaceutically acceptable carrier.

81. An isolated protein comprising amino acids 1 to 162 of SEQ ID NO:26.

82. The isolated protein of claim 81, which comprises amino acids -38 to 162 of SEQ ID NO:26.

83. The isolated protein of claim 81, which is produced by a recombinant host cell.

84. The isolated protein of claim 81, which comprises a heterologous polypeptide.

85. The isolated protein of claim 84, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

86. A composition comprising the isolated protein of claim 81 and a pharmaceutically acceptable carrier.

87. An isolated protein comprising 30 contiguous amino acids of SEQ ID NO:26.

88. The isolated protein of claim 87, which comprises 50 contiguous amino acids of SEQ ID NO:26.

666290-06904E60

sub
C50

B4
Cont.

sub
E6

89. The isolated protein of claim 87, which is produced by a recombinant host cell.

90. The isolated protein of claim 87, which comprises a heterologous polypeptide.

91. The isolated protein of claim 90, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

92. A composition comprising the isolated protein of claim 87 and a pharmaceutically acceptable carrier.

93. An isolated protein comprising an amino acid sequence at least 95% identical to amino acids 1 to 164 of SEQ ID NO:2;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids 1 to 164 of SEQ ID NO:2 and that allow gaps of up to 5% of the total number of residues in amino acids 1 to 164 of SEQ ID NO:2.

94. The isolated protein of claim 93, comprising amino acids 1 to 164 of SEQ ID NO:2.

95. The isolated protein of claim 93, wherein said amino acid sequence is at least 95% identical to amino acids 1 to 247 of SEQ ID NO:2;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids 1 to 247 of SEQ ID NO:2 and that

06904E60

By
Cont

allow gaps of up to 5% of the total number of residues in amino acids 1 to 247 of SEQ ID NO:2.

96. The isolated protein of claim 95, comprising amino acids 1 to 247 of SEQ ID NO:2.

97. The isolated protein of claim 93, wherein said amino acid sequence is at least 95% identical to amino acids -35 to 247 of SEQ ID NO:2;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids -35 to 247 of SEQ ID NO:2 and that allow gaps of up to 5% of the total number of residues in amino acids -35 to 247 of SEQ ID NO:2.

98. The isolated protein of claim 97, comprising amino acids -35 to 247 of SEQ ID NO:2.

99. The isolated protein of claim 93, wherein said amino acid sequence is at least 95% identical to amino acids -36 to 247 of SEQ ID NO:2;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids -36 to 247 of SEQ ID NO:2 and that allow gaps of up to 5% of the total number of residues in amino acids -36 to 247 of SEQ ID NO:2.

100. The isolated protein of claim 99, comprising amino acids -36 to 247 of SEQ ID NO:2.

666290-06904E60

B4
Cont.

101. The isolated protein of claim 93, which is produced by a recombinant host cell.
102. The isolated protein of claim 93, which comprises a heterologous polypeptide.
103. The isolated protein of claim 102, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
104. A composition comprising the isolated protein of claim 93 and a pharmaceutically acceptable carrier.
105. An isolated protein comprising an amino acid sequence at least 95% identical to the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97059; wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97059 and that allow gaps of up to 5% of the total number of residues of the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97059.
106. The isolated protein of claim 105, wherein said amino acid sequence is at least 95% identical to the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97059; wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of the complete amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97059 and that allow gaps of up to 5% of the total number

655290" 06904E60
B4
cont.

107. The isolated protein of claim 105, which is produced by a recombinant host cell.

108. The isolated protein of claim 105, which comprises a heterologous polypeptide.

109. The isolated protein of claim 108, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

110. A composition comprising the isolated protein of claim 105 and a pharmaceutically acceptable carrier.

111. An isolated protein comprising an amino acid sequence at least 95% identical to amino acids 1 to 149 of SEQ ID NO:5;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids 1 to 149 of SEQ ID NO:5 and that allow gaps of up to 5% of the total number of residues in amino acids 1 to 149 of SEQ ID NO:5.

112. The isolated protein of claim 111, comprising amino acids 1 to 149 of SEQ ID NO:5.

Figure 1 consists of seven sub-graphs, labeled (a) through (g), each showing the time course of plasma concentrations over a 12-hour period. The x-axis for all graphs is 'Time (h)' ranging from 0 to 12. The y-axis represents concentration in mg/L, with varying scales for each graph. Graph (a) shows the concentration of the parent drug, which decreases over time. Graphs (b) through (g) show the concentrations of various metabolites, with some showing an increase and others a decrease over time. Each graph includes data points with error bars and a fitted curve.

B4
Cont.

113. The isolated protein of claim 111, wherein said amino acid sequence is at least 95% identical to amino acids -35 to 149 of SEQ ID NO:5;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids -35 to 149 of SEQ ID NO:5 and that allow gaps of up to 5% of the total number of residues in amino acids -35 to 149 of SEQ ID NO:5.

114. The isolated protein of claim 113, comprising amino acids -35 to 149 of SEQ ID NO:5.

115. The isolated protein of claim 111, wherein said amino acid sequence is at least 95% identical to amino acids -36 to 149 of SEQ ID NO:5;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids -36 to 149 of SEQ ID NO:5 and that allow gaps of up to 5% of the total number of residues in amino acids -36 to 149 of SEQ ID NO:5.

116. The isolated protein of claim 115, comprising amino acids -36 to 149 of SEQ ID NO:5.

117. The isolated protein of claim 111, which is produced by a recombinant host cell.

118. The isolated protein of claim 111, which comprises a heterologous polypeptide.

06904E60 06904E60

BY
cont.

119. The isolated protein of claim 118, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

120. A composition comprising the isolated protein of claim 111 and a pharmaceutically acceptable carrier.

121. An isolated protein comprising an amino acid sequence at least 95% identical to the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97058; wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97058 and that allow gaps of up to 5% of the total number of residues of the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97058.

122. The isolated protein of claim 121, wherein said amino acid sequence is at least 95% identical to the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97058;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of the complete amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97058 and that allow gaps of up to 5% of the total number of residues of the complete amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97058.

00340690 06904E60

B4
Cont.

123. The isolated protein of claim 121, which is produced by a recombinant host cell.
124. The isolated protein of claim 121, which comprises a heterologous polypeptide.
125. The isolated protein of claim 124, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
126. A composition comprising the isolated protein of claim 121 and a pharmaceutically acceptable carrier.
127. An isolated protein comprising an amino acid sequence at least 95% identical to amino acids 2 to 136 of SEQ ID NO:8,
wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids 2 to 136 of SEQ ID NO:8 and that allow gaps of up to 5% of the total number of residues in amino acids 2 to 136 of SEQ ID NO:8.
128. The isolated protein of claim 127, comprising amino acids 2 to 136 of SEQ ID NO:8.
129. The isolated protein of claim 127, wherein said amino acid sequence is at least 95% identical to amino acids 1 to 136 of SEQ ID NO:8;

By 066290 06904E60
Cant

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of amino acids 1 to 136 of SEQ ID NO:8 and that allow gaps of up to 5% of the total number of residues in amino acids 1 to 136 of SEQ ID NO:8.

130. The isolated protein of claim 129, comprising amino acids 1 to 136 of SEQ ID NO:8.

131. The isolated protein of claim 127, which is produced by a recombinant host cell.

132. The isolated protein of claim 127, which comprises a heterologous polypeptide.

133. The isolated protein of claim 132, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

134. A composition comprising the isolated protein of claim 127 and a pharmaceutically acceptable carrier.

135. An isolated protein comprising an amino acid sequence at least 95% identical to the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97057; wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97057 and that allow gaps of up to 5% of the total number

066230-06904E60

B4
Cont

of residues of the mature amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97057.

136. The isolated protein of claim 135, wherein said amino acid sequence is at least 95% identical to the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97057;

wherein % identity is determined using the Bestfit program with parameters that calculate % identity over the full length of the complete amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97057 and that allow gaps of up to 5% of the total number of residues of the complete amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97057.

137. The isolated protein of claim 135, which is produced by a recombinant host cell.

138. The isolated protein of claim 135, which comprises a heterologous polypeptide.

139. The isolated protein of claim 138, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

140. A composition comprising the isolated protein of claim 135 and a pharmaceutically acceptable carrier.

0650290-06504260

B4
cont.

141. An isolated protein comprising an amino acid sequence selected from the group consisting of:

- (a) amino acids 3 to 34 in SEQ ID NO:2;
- (b) amino acids 70 to 84 in SEQ ID NO:2;
- (c) amino acids 106 to 153 in SEQ ID NO:2; and
- (d) amino acids 240 to 247 in SEQ ID NO:2.

142. The isolated protein of claim 141, wherein said amino acid sequence is (a).

143. The isolated protein of claim 141, wherein said amino acid sequence is (b).

144. The isolated protein of claim 141, wherein said amino acid sequence is (c).

145. The isolated protein of claim 141, wherein said amino acid sequence is (d).

146. The isolated protein of claim 141, which is produced by a recombinant host cell.

147. The isolated protein of claim 141, which comprises a heterologous polypeptide.

148. The isolated protein of claim 147, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

066290-06904260

BY
Cmt.

149. A composition comprising the isolated protein of claim 141 and a pharmaceutically acceptable carrier.
150. An isolated protein comprising 15 contiguous amino acids of SEQ ID NO:2.
151. The isolated protein of claim 150, which is produced by a recombinant host cell.
152. The isolated protein of claim 150, which comprises a heterologous polypeptide.
153. The isolated protein of claim 152, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.
154. A composition comprising the isolated protein of claim 150 and a pharmaceutically acceptable carrier.
155. An isolated protein comprising an amino acid sequence selected from the group consisting of:
- (a) amino acid 3 to 34 in SEQ ID NO:5;
 - (b) amino acid 63 to 100 in SEQ ID NO:5; and
 - (c) amino acid 135 to 149 in SEQ ID NO:5;
156. The isolated protein of claim 155, wherein said amino acid sequence is (a).

06504260

B4
cont.

157. The isolated protein of claim 155, wherein said amino acid sequence is (b).

158. The isolated protein of claim 155, wherein said amino acid sequence is (c).

159. The isolated protein of claim 155, which is produced by a recombinant host cell.

160. The isolated protein of claim 155, which comprises a heterologous polypeptide.

161. The isolated protein of claim 160, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

162. A composition comprising the isolated protein of claim 155 and a pharmaceutically acceptable carrier.

163. An isolated protein comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid 56 to 68 in SEQ ID NO:8; and
- (b) amino acid 93 to 136 in SEQ ID NO:8.

164. The isolated protein of claim 163, wherein said amino acid sequence is (a).

165. The isolated protein of claim 163, wherein said amino acid sequence is (b).

066290-06904660

B4
cont.

166. The isolated protein of claim 163, which is produced by a recombinant host cell.

167. The isolated protein of claim 163, which comprises a heterologous polypeptide.

168. The isolated protein of claim 167, wherein said a heterologous polypeptide comprises the Fc portion of an antibody molecule.

169. A composition comprising the isolated protein of claim 163 and a pharmaceutically acceptable carrier.

170. An isolated protein comprising an amino acid sequence encoded by a first polynucleotide which hybridizes to a second polynucleotide consisting of the coding region of SEQ ID NO:25, or the complement thereof, under conditions comprising:

(a) incubating overnight at 65°C in a solution consisting of 0.5M NaPO₄, pH 7.4 and 7% SDS; and

(b) washing at 60°C in a solution consisting of 0.5 X SSC with 0.1% SDS.

171. The isolated protein of claim 170, which is produced by a recombinant host cell.

172. The isolated protein of claim 170, which comprises a heterologous polypeptide.

6562930 06904E60

B4
cont.